Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
WOCKHARDT TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
WOCKHARDT Mar-23 |
TEVA PHARMA Dec-13 |
WOCKHARDT/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 316 | 3,477 | - | |
Low | Rs | 145 | 3,020 | - | |
Sales per share (Unadj.) | Rs | 184.0 | 1,995.2 | - | |
Earnings per share (Unadj.) | Rs | -43.1 | 124.6 | - | |
Cash flow per share (Unadj.) | Rs | -25.7 | 285.9 | - | |
Dividends per share (Unadj.) | Rs | 0 | 109.11 | - | |
Avg Dividend yield | % | 0 | 3.4 | 0.0% | |
Book value per share (Unadj.) | Rs | 231.7 | 2,216.3 | - | |
Shares outstanding (eoy) | m | 144.09 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 1.6 | 76.9% | |
Avg P/E ratio | x | -5.3 | 26.1 | -20.5% | |
P/CF ratio (eoy) | x | -9.0 | 11.4 | -79.0% | |
Price / Book Value ratio | x | 1.0 | 1.5 | 67.9% | |
Dividend payout | % | 0 | 87.5 | -0.0% | |
Avg Mkt Cap | Rs m | 33,202 | 2,754,567 | 1.2% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 6,370 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,645.0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,351.7 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 26,510 | 1,691,953 | 1.6% | |
Other income | Rs m | 1,220 | 0 | - | |
Total revenues | Rs m | 27,730 | 1,691,953 | 1.6% | |
Gross profit | Rs m | -1,930 | 463,342 | -0.4% | |
Depreciation | Rs m | 2,510 | 136,762 | 1.8% | |
Interest | Rs m | 3,020 | 33,233 | 9.1% | |
Profit before tax | Rs m | -6,240 | 293,347 | -2.1% | |
Minority Interest | Rs m | 0 | 1,333 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -192,566 | -0.0% | |
Tax | Rs m | -30 | -3,581 | 0.8% | |
Profit after tax | Rs m | -6,210 | 105,695 | -5.9% | |
Gross profit margin | % | -7.3 | 27.4 | -26.6% | |
Effective tax rate | % | 0.5 | -1.2 | -39.4% | |
Net profit margin | % | -23.4 | 6.2 | -375.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,140 | 1,142,739 | 1.7% | |
Current liabilities | Rs m | 34,350 | 996,565 | 3.4% | |
Net working cap to sales | % | -57.4 | 8.6 | -664.1% | |
Current ratio | x | 0.6 | 1.1 | 48.6% | |
Inventory Days | Days | 39 | 91 | 43.4% | |
Debtors Days | Days | 11 | 96 | 11.4% | |
Net fixed assets | Rs m | 48,670 | 552,629 | 8.8% | |
Share capital | Rs m | 720 | 4,165 | 17.3% | |
Net worth | Rs m | 33,380 | 1,879,439 | 1.8% | |
Long term debt | Rs m | 2,240 | 865,133 | 0.3% | |
Total assets | Rs m | 70,750 | 3,866,655 | 1.8% | |
Interest coverage | x | -1.1 | 9.8 | -10.8% | |
Debt to equity ratio | x | 0.1 | 0.5 | 14.6% | |
Sales to assets ratio | x | 0.4 | 0.4 | 85.6% | |
Return on assets | % | -4.5 | 3.6 | -125.5% | |
Return on equity | % | -18.6 | 5.6 | -330.8% | |
Return on capital | % | -9.0 | 4.9 | -183.3% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 1,530 | 269,610 | 0.6% | |
From Investments | Rs m | -1,250 | -95,534 | 1.3% | |
From Financial Activity | Rs m | -3,150 | -323,415 | 1.0% | |
Net Cashflow | Rs m | -2,800 | -149,339 | 1.9% |
Compare WOCKHARDT With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare WOCKHARDT With: SYNCOM FORMULATIONS MEDICO REMEDIES GRANULES INDIA PARMAX PHARMA SUPRIYA LIFESCIENCE
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.